Join Growin Stock Community!

Haleon plcHLN.US Overview

US StockHealthcare
(No presentation for HLN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HLN AI Insights

HLN Overall Performance

HLN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HLN Recent Performance

-2.12%

Haleon plc

0.05%

Avg of Sector

-0.31%

S&P500

HLN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HLN Key Information

HLN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HLN Profile

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Price of HLN

HLN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HLN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.64
PE Ratio (TTM)
22.14
Forward PE
30.33
PS Ratio (TTM)
4.47
PB Ratio
2.23
Price-to-FCF
12.73
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.66%
Net Margin
14.94%
Revenue Growth (YoY)
13.49%
Profit Growth (YoY)
16.99%
3-Year Revenue Growth
13.29%
3-Year Profit Growth
17.59%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.64
PE Ratio (TTM)
22.14
Forward PE
30.33
PS Ratio (TTM)
4.47
PB Ratio
2.23
Price-to-FCF
12.73
Gross Margin
64.66%
Net Margin
14.94%
Revenue Growth (YoY)
13.49%
Profit Growth (YoY)
16.99%
3-Year Revenue Growth
13.29%
3-Year Profit Growth
17.59%

  • When is HLN's latest earnings report released?

    The most recent financial report for Haleon plc (HLN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HLN's short-term business performance and financial health. For the latest updates on HLN's earnings releases, visit this page regularly.

  • Where does HLN fall in the P/E River chart?

    According to historical valuation range analysis, Haleon plc (HLN)'s current price-to-earnings (P/E) ratio is 9.75, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of HLN?

    According to the latest financial report, Haleon plc (HLN) reported an Operating Profit of 1.25B with an Operating Margin of 22.67% this period, representing a growth of 18.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HLN's revenue growth?

    In the latest financial report, Haleon plc (HLN) announced revenue of 5.52B, with a Year-Over-Year growth rate of -0.42%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does HLN have?

    As of the end of the reporting period, Haleon plc (HLN) had total debt of 8.59B, with a debt ratio of 0.26. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HLN have?

    At the end of the period, Haleon plc (HLN) held Total Cash and Cash Equivalents of 1.32B, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HLN go with three margins increasing?

    In the latest report, Haleon plc (HLN) achieved the “three margins increasing” benchmark, with a gross margin of 65.03%%, operating margin of 22.67%%, and net margin of 15.51%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HLN's profit trajectory and future growth potential.

  • Is HLN's EPS continuing to grow?

    According to the past four quarterly reports, Haleon plc (HLN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.